Johnson et al. noted exacerbations of rheumatoid arthritis and inflammatory bowel disease (IBD), as well as increased occurrence of IRAE, during anti-CTLA-4 monotherapy [7]. This evidence concerns the gene CTLA4 and rheumatoid arthritis.